Clinical trial
TMC125-C203: Phase II Randomized (Patients Are Assigned Different Treatments…
NCT00412646 · Tibotec Pharmaceuticals, Ireland, Industry · Completed
Key facts
| NCT number | NCT00412646 |
|---|---|
| Title | TMC125-C203: Phase II Randomized (Patients Are Assigned Different Treatments Based on Chance), Placebo Controlled Dose Escalating Trial of TMC125 in HIV-1 Infected Patients |
| Official title | A Randomized, Placebo-controlled Phase II Trial in HIV-1-infected, NRTI-, PI and NNRTI-experienced Subjects to Evaluate the Safety, Tolerability and Efficacy of Different Doses of TMC125 b.i.d. on Top of an Individually Optimized Antiretroviral Therapy by Means of a 2-stage Dose-escalating Design |
| Lead sponsor | Tibotec Pharmaceuticals, Ireland, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Anti-Retroviral Agents, HIV-1 |
| Intervention type | Drug |
| Interventions | TMC125 |
| Enrollment | 260 |
| Start date | Jun 1, 2002 |
| Completion | Nov 1, 2006 |
| First posted | Dec 18, 2006 |
| Last update posted | Apr 28, 2010 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: